299 related articles for article (PubMed ID: 10953132)
21. Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: relationships with tumor recurrence and survival.
Rosati G; Chiacchio R; Reggiardo G; De Sanctis D; Manzione L
Tumour Biol; 2004; 25(5-6):258-63. PubMed ID: 15627889
[TBL] [Abstract][Full Text] [Related]
22. Bcl-2, p53 and MIB-1 expression in normal and neoplastic parathyroid tissues.
Naccarato AG; Marcocci C; Miccoli P; Bonadio AG; Cianferotti L; Vignali E; Cipollini G; Viacava P
J Endocrinol Invest; 1998 Mar; 21(3):136-41. PubMed ID: 9591207
[TBL] [Abstract][Full Text] [Related]
23. p53 over-expression identifies a subset of nodal peripheral T-cell lymphomas with a distinctive biological profile and poor clinical outcome.
Pescarmona E; Pignoloni P; Puopolo M; Martelli M; Addesso M; Guglielmi C; Baroni CD
J Pathol; 2001 Oct; 195(3):361-6. PubMed ID: 11673835
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of Bcl-2 in clinically localized prostate cancer.
Bubendorf L; Sauter G; Moch H; Jordan P; Blöchlinger A; Gasser TC; Mihatsch MJ
Am J Pathol; 1996 May; 148(5):1557-65. PubMed ID: 8623924
[TBL] [Abstract][Full Text] [Related]
25. Tumor cell proliferation and survival in patients with prostate cancer followed expectantly.
Borre M; Bentzen SM; Nerstrøm B; Overgaard J
J Urol; 1998 May; 159(5):1609-14. PubMed ID: 9554364
[TBL] [Abstract][Full Text] [Related]
26. Diffuse myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma: a tissue microarray study of 71 primary tumors including correlation with molecular phenotype.
Heerema-McKenney A; Wijnaendts LC; Pulliam JF; Lopez-Terrada D; McKenney JK; Zhu S; Montgomery K; Mitchell J; Marinelli RJ; Hart AA; van de Rijn M; Linn SC
Am J Surg Pathol; 2008 Oct; 32(10):1513-22. PubMed ID: 18708938
[TBL] [Abstract][Full Text] [Related]
27. Primary gastrointestinal B-cell lymphoma. A clincopathological and immunohistochemical study of 61 cases with an evaluation of prognostic parameters.
Krugmann J; Dirnhofer S; Gschwendtner A; Berresheim U; Greil R; Krugmann K; Fend F
Pathol Res Pract; 2001; 197(6):385-93. PubMed ID: 11432665
[TBL] [Abstract][Full Text] [Related]
28. Apoptosis control and proliferation marker in human normal and neoplastic adrenocortical tissues.
Bernini GP; Moretti A; Viacava P; Bonadio AG; Iacconi P; Miccoli P; Salvetti A
Br J Cancer; 2002 May; 86(10):1561-5. PubMed ID: 12085205
[TBL] [Abstract][Full Text] [Related]
29. Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis.
Heidenreich A; Sesterhenn IA; Mostofi FK; Moul JW
Cancer; 1998 Sep; 83(5):1002-11. PubMed ID: 9731905
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of p53, p21/WAF1, Bcl-2, Bax, Bak and Ki-67 immunoreactivity in pT1 G3 urothelial bladder carcinomas.
Wolf HK; Stöber C; Hohenfellner R; Leissner J
Tumour Biol; 2001; 22(5):328-36. PubMed ID: 11553864
[TBL] [Abstract][Full Text] [Related]
31. Muscle invasive schistosomal squamous cell carcinoma of the urinary bladder: frequency and prognostic significance of p53, BCL-2, HER2/neu, and proliferation (MIB-1).
Badr KM; Nolen JD; Derose PB; Cohen C
Hum Pathol; 2004 Feb; 35(2):184-9. PubMed ID: 14991535
[TBL] [Abstract][Full Text] [Related]
32. Prognostic factors in resectable pancreatic cancer: p53 and bcl-2.
Bold RJ; Hess KR; Pearson AS; Grau AM; Sinicrope FA; Jennings M; McConkey DJ; Bucana CD; Cleary KR; Hallin PA; Chiao PJ; Abbruzzese JL; Evans DB
J Gastrointest Surg; 1999; 3(3):263-77. PubMed ID: 10481119
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Factors of Prostate Cancer in Tunisian Men: Immunohistochemical Study.
Missaoui N; Abdelkarim SB; Mokni M; Hmissa S
Asian Pac J Cancer Prev; 2016; 17(5):2655. PubMed ID: 27268646
[TBL] [Abstract][Full Text] [Related]
34. p53 immunoreactivity as prognostic marker for cancer-specific survival in prostate cancer.
Stattin P; Bergh A; Karlberg L; Nordgren H; Damber JE
Eur Urol; 1996; 30(1):65-72. PubMed ID: 8854070
[TBL] [Abstract][Full Text] [Related]
35. p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy.
Stackhouse GB; Sesterhenn IA; Bauer JJ; Mostofi FK; Connelly RR; Srivastava SK; Moul JW
J Urol; 1999 Dec; 162(6):2040-5. PubMed ID: 10569564
[TBL] [Abstract][Full Text] [Related]
36. The spectrum of neuroendocrine differentiation among gastrointestinal carcinoids: importance of histologic grading, MIB-1, p53, and bcl-2 immunoreactivity.
Moyana TN; Xiang J; Senthilselvan A; Kulaga A
Arch Pathol Lab Med; 2000 Apr; 124(4):570-6. PubMed ID: 10747315
[TBL] [Abstract][Full Text] [Related]
37. Bcl-2 protein expression is associated with p27 and p53 protein expressions and MIB-1 counts in breast cancer.
Tsutsui S; Yasuda K; Suzuki K; Takeuchi H; Nishizaki T; Higashi H; Era S
BMC Cancer; 2006 Jul; 6():187. PubMed ID: 16839413
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of immunohistochemical staining of p53, bcl-2, and Ki-67 in small cell lung cancer.
Paik KH; Park YH; Ryoo BY; Yang SH; Lee JC; Kim CH; Ki SS; Kim JM; Park MJ; Ahn HJ; Choi W; Chung JH
J Korean Med Sci; 2006 Feb; 21(1):35-9. PubMed ID: 16479062
[TBL] [Abstract][Full Text] [Related]
39. MIB-1, p53, bcl-2, and WAF-1 expression in pelvic lymph nodes and primary tumors in early stage cervical carcinomas: correlation with clinical outcome.
Graflund M; Sorbe B; Karlsson M
Int J Oncol; 2002 May; 20(5):1041-7. PubMed ID: 11956602
[TBL] [Abstract][Full Text] [Related]
40. Androgen receptor expression in relation to apoptosis and the expression of cell cycle related proteins in prostate cancer.
Amirghofran Z; Monabati A; Gholijani N
Pathol Oncol Res; 2004; 10(1):37-41. PubMed ID: 15029260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
